ClinicalTrials.gg
CompletedNCT03336528Updated Mar 31, 2022Results posted

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

A Phase 4 interventional study of Degludec and Glargine in Type 2 Diabetes, sponsored by Emory University. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-31.

Sponsored by Emory University · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
51st of 70
180 · median 384
Started
2018
with 4 others
Phase 4
8 of 70
1 open now
Registered
58th of 70
by date
Lead sponsor
1 of 70
Emory University

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 51st largest by enrollment, is one of 5 that started in 2018, is one of 8 in phase 4, and was the 58th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to find out if treatment with degludec insulin when compared to glargine U100 insulin will result in similar blood sugar control in patients with diabetes who are admitted to the hospital and then transition to home after discharge from the hospital.

Read the detailed description

Degludec is a new generation basal insulin analog with a longer duration of action compared to insulin glargine. Several outpatient trials have reported that treatment with degludec results in comparable improvement in HbA1c levels and in lower rates of hypoglycemia compared to glargine U100 insulin. However, no previous studies have compared the safety and efficacy of the long-acting basal insulin degludec in the inpatient management of patients with diabetes. It is expected that a large number of patients with diabetes will be started on or transitioned to this new insulin formulation so acquiring knowledge on the safety and efficacy of degludec insulin is of great clinical interest. Accordingly, the proposed study will provide novel and clinically useful information on the efficacy (assessed as blood glucose control) and safety (assessed as hypoglycemia) of degludec in the inpatient setting and after hospital discharge in general medicine and surgery patients with Type 2 Diabetes (T2D).

Participants will be randomized to receive either a basal bolus with degludec or glargine U100 once daily during hospitalization. All participants will receive aspart insulin before meals. Participants with poorly controlled diabetes during the inpatient portion of the study will be invited to participate in the outpatient portion of the study. Participants in the outpatient portion of the study will be discharged on their preadmission oral antidiabetic medications plus degludec or glargine once daily, based on the study medication they were randomized to take during the inpatient portion of the study.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Long-acting insulin analog
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females > 18 years of age who are admitted to a general medicine or surgical service
  2. A known history of T2D treated either with diet alone, oral monotherapy, any combination of oral antidiabetic agents, short-acting glucagon-like peptide-1 receptor agonists (GLP-1 RA) or insulin therapy except for degludec and glargine U300
  3. Subjects with diet alone and >7.0%
  4. Medical and surgical patients expected to be admitted length of stay (LOS) longer than 2 days
  5. Subjects must have a randomization BG > 140 mg and \< 400 mg/dL without laboratory evidence of diabetic ketoacidosis (bicarbonate \< 18 milliequivalent (mEq)/L, potential of hydrogen (pH) \< 7.30, or positive serum or urinary ketones)
  6. Signed, and HIPAA documentation prior to any study procedures

Exclusion criteria

Exclusion Criteria:

  1. Subjects with increased BG concentration, but without a known history of diabetes (stress hyperglycemia)
  2. Subjects treated with diet alone (no antidiabetic agents) and admission \<7%
  3. Admission or pre-randomization BG≥400 mg/dL
  4. Subjects with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic state, or ketonuria
  5. Patients treated with degludec or glargine U300, or with long-acting weekly GLP-1 RA (weekly exenatide, dulaglutide or albiglutide)
  6. Patients with acute critical or surgical illness admitted to the ICU except for observation (\<24 hours and did not require vasopressors and/or mechanical ventilation)
  7. Patients with history of hepatic disease (diagnosed liver cirrhosis and portal hypertension), ongoing therapy (equal to a prednisone dose ≥5 mg/day), or impaired renal function (\< 30 ml/min), or congestive heart failure (- IV)
  8. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
  9. Female subjects who are pregnant or breast feeding at time of enrollment into the study
  10. Known or suspected allergy to trial medication(s), , or related products
  11. Previous participation in this trial
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Degludec inpatient

    Study participants treated with insulin prior to admission will receive 80% or 100% of the total daily dose (TDD) given as a basal bolus regimen with degludec once daily plus rapid-acting aspart insulin before meals.

    Drug: Degludec · Drug: Aspart

  • Active comparator
    Glargine U100 inpatient

    Study participants treated with insulin prior to admission will receive 80% or 100% of the total daily dose (TDD) given as basal bolus regimen with glargine once daily plus rapid-acting aspart insulin before meals.

    Drug: Glargine · Drug: Aspart

Interventions

  • Degludec is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner blood glucose (BG) between 100 mg/dL and 180 mg/dL.

    Also known as: Tresiba

  • Glargine is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner BG between 100 mg/dL and 180 mg/dL.

    Also known as: Lantus

  • DrugAspart

    Aspart insulin will be given in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, aspart insulin dose will be held.

    Also known as: Novolog

06

What researchers measure

Primary outcomes

  1. Mean Daily Blood Glucose Concentration in Hospitalized Patients

    Blood glucose was measured before each meal and at bedtime among hospitalized study participants. Mean daily blood glucose concentration was calculated to determine differences in inpatient glycemic control in general medicine and surgery patients with Type 2 Diabetes (T2D) treated with basal bolus regimen with insulin degludec or glargine once daily plus aspart insulin before meals. A random (non-fasting) blood glucose measurement of 140 mg/dL or less is considered normal, while a measurement of 200 mg/dL or more indicates diabetes.

    Time frame: Baseline, up to the first 10 days of therapy

  2. Mean Daily Blood Glucose Concentration in Discharged Patients.

    Blood glucose was measured before each meal and at bedtime, after participants were discharged from the hospital. Mean daily blood glucose concentration was calculated to determine differences in outpatient glycemic control in patients with Type 2 Diabetes (T2D) treated with basal bolus regimen with insulin degludec or glargine once daily plus aspart insulin before meals. Information was collected via bi-weekly phone interviews and during the outpatient study visits at Weeks 4 and 12.

    Time frame: Day after hospital discharge to 4 weeks after discharge, 4 to 12 weeks after hospital discharge

Secondary outcomes

  1. Number of Blood Glucose Point-of-care Test Results Between 70 and 180 mg/dL in Hospitalized Patients

    Blood glucose was measured with point-of-care testing before each meal and at bedtime, and the count of blood glucose test results between 70 mg/dL and 180 mg/dL was determined.

    Time frame: During the first 10 days of therapy

  2. Number of Participants With an Episode of Hypoglycemia While Hospitalized

    Blood glucose (BG) was measured before each meal and at bedtime. The number of participants with at least one hypoglycemic episode, defined as BG of 54 to 70 mg/dL, is presented here.

    Time frame: During the first 10 days of therapy

  3. Number of Participants With an Episode of Clinically Significant Hypoglycemia While Hospitalized

    Blood glucose was measured before each meal and at bedtime. The number of participants with at least one episode of clinically significant hypoglycemia, defined as BG \< 54 mg/dL, is presented here.

    Time frame: During the first 10 days of therapy

  4. Number of Participants With an Episode of Severe Hypoglycemia While Hospitalized

    Blood glucose as measured before each meal and at bedtime. The number of participants with at least one episode of severe hypoglycemia, defined as BG \< 40 mg/dL, is presented here.

    Time frame: During the first 10 days of therapy

  5. Number of Participants With an Episode of Severe Hyperglycemia While Hospitalized

    Blood glucose was measured before each meal and at bedtime. The number of participants who experienced at least one episode of severe hyperglycemia, defined as BG \> 240 mg/dL, is presented here.

    Time frame: During the first 10 days of therapy

  6. Daily Dose of Insulin in Hospitalized Patients

    Electronic medical records and nursing records documented the day day and time of insulin administration, including the basal study drug given once daily (degludec or glargine), prandial insulin given before meals (aspart), and supplemental insulin given to correct hyperglycemia. The mean daily doses of basal insulin, prandial insulin, and total daily dose of insulin given to hospitalized patients are presented here.

    Time frame: During the first 10 days of therapy

  7. Hemoglobin A1c (HbA1c) in Discharged Patients

    The HbA1C test reflects the average of a person's blood glucose levels over the past 3 months by measuring the percentage of red blood cells (RBCs) with glycated hemoglobin (hemoglobin with glucose bonded to it). Participants with HbA1C ≥ 7.5% were followed for 12 weeks after hospital discharge. Samples for HbA1C were drawn at 4 and 12 weeks post-discharge. An HbA1c measurement below 5.7% is considered normal, while a measurement of 6.5% or greater indicates diabetes.

    Time frame: 4 and 12 weeks after hospital discharge

  8. Number of Hypoglycemia Episodes in Discharged Patients

    Blood glucose was measured before each meal and at bedtime. The number of hypoglycemia episodes, defined as BG \< 70 mg/dL, was recorded via bi-weekly phone interviews and during 4 and 12 week outpatient study visits.

    Time frame: Up to 12 weeks after hospital discharge

  9. Number of Clinically Significant Hypoglycemia Episodes in Discharged Patients

    Blood glucose will be measured before each meal and at bedtime. The number of episodes of clinically significant hypoglycemia, defined as BG \< 54 mg/dL, are presented here.

    Time frame: Up to 12 weeks after hospital discharge

  10. Number of Episodes of Severe Hyperglycemia in Discharged Patients

    Blood glucose was measured before each meal and at bedtime. The number of episodes of severe hyperglycemia, defined as BG \> 240 mg/dL, are presented here.

    Time frame: Up to 12 weeks after hospital discharge

Other outcomes

  1. Number of Participants Experiencing Cardiac Complications During Hospitalization

    Cardiac complications during hospitalization were examined as a composite of complications, defined as myocardial infarction, cardiac arrhythmia requiring medical treatment, or cardiac arrest. The number of participants experiencing cardiac complications while hospitalized patients is presented here.

    Time frame: During the first 10 days of therapy

  2. Number of Participants With Acute Kidney Injury During Hospitalization

    Acute kidney injury defined as an increase in serum creatinine ≥ 0.3 mg/dL from baseline or ≥1.5 times baseline creatinine, per Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. The number of participants experiencing acute kidney injury during hospitalization is presented here.

    Time frame: During the first 10 days of therapy

  3. Length of Hospital Stay

    The length of hospital in days is presented here.

    Time frame: Duration of hospital stay (an average of 10 days)

  4. Number of Participants Who Died During Hospitalization

    Hospital mortality is evaluated as the number of deaths among participants during hospitalization.

    Time frame: Duration of hospital stay (an average of 10 days)

  5. Number of Participants Experiencing Acute Kidney Injury in Discharged Patients

    Acute kidney injury defined as an increase in serum creatinine ≥ 0.3 mg/dL from baseline or ≥1.5 times baseline creatinine, per Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. The number of participants experiencing acute kidney injury after hospital discharge is presented here.

    Time frame: Up to 12 weeks after hospital discharge

07

Results

Posted Mar 31, 2022

Participant flow

Participants were recruited from four study sites in the United States: Emory University Hospital and Grady Memorial Hospital in Atlanta, Georgia, Icahn School of Medicine at Mount Sinai in New York, New York, and Providence Medical Research Center in Spokane, Washington. Enrollment began on January 2, 2018 and all follow up was complete by March 1, 2021.

Participant flow — Overall Study
MilestoneDegludecGlargine
Started9288
Participated in optional outpatient study7259
Completed8279
Not completed109
Withdrew: Protocol violation11
Withdrew: Discharged within 48 hours of study medication86
Withdrew: Did not receive study medication12

Outcome measures

PrimaryMean Daily Blood Glucose Concentration in Hospitalized Patients

Blood glucose was measured before each meal and at bedtime among hospitalized study participants. Mean daily blood glucose concentration was calculated to determine differences in inpatient glycemic control in general medicine and surgery patients with Type 2 Diabetes (T2D) treated with basal bolus regimen with insulin degludec or glargine once daily plus aspart insulin before meals. A random (non-fasting) blood glucose measurement of 140 mg/dL or less is considered normal, while a measurement of 200 mg/dL or more indicates diabetes.

Time frame:
Baseline, up to the first 10 days of therapy
Reported as:
Mean · mg/dL
Mean Daily Blood Glucose Concentration in Hospitalized Patients
mg/dLDegludecGlargine
Baseline219.50 ± 50.21218.19 ± 54.56
Day 1 up to Day 10179.75 ± 38.45180.67 ± 45.10
PrimaryMean Daily Blood Glucose Concentration in Discharged Patients.

Blood glucose was measured before each meal and at bedtime, after participants were discharged from the hospital. Mean daily blood glucose concentration was calculated to determine differences in outpatient glycemic control in patients with Type 2 Diabetes (T2D) treated with basal bolus regimen with insulin degludec or glargine once daily plus aspart insulin before meals. Information was collected via bi-weekly phone interviews and during the outpatient study visits at Weeks 4 and 12.

Time frame:
Day after hospital discharge to 4 weeks after discharge, 4 to 12 weeks after hospital discharge
Reported as:
Mean · mg/dL
Mean Daily Blood Glucose Concentration in Discharged Patients.
mg/dLDegludec During HospitalizationGlargine During Hospitalization
Day after discharge up to the 4 week post-discharge study visit157.0 ± 46.4143.0 ± 42.5
4 week post-discharge up to the 12 week post-discharge study visit148.7 ± 43.6133.8 ± 44.2
SecondaryNumber of Blood Glucose Point-of-care Test Results Between 70 and 180 mg/dL in Hospitalized Patients

Blood glucose was measured with point-of-care testing before each meal and at bedtime, and the count of blood glucose test results between 70 mg/dL and 180 mg/dL was determined.

Time frame:
During the first 10 days of therapy
Reported as:
Count of units · Blood Glucose Point-of-Care Test
Number of Blood Glucose Point-of-care Test Results Between 70 and 180 mg/dL in Hospitalized Patients
Blood Glucose Point-of-Care TestDegludecGlargine
Number of Blood Glucose Point-of-care Test Results Between 70 and 180 mg/dL in Hospitalized Patients758789
SecondaryNumber of Participants With an Episode of Hypoglycemia While Hospitalized

Blood glucose (BG) was measured before each meal and at bedtime. The number of participants with at least one hypoglycemic episode, defined as BG of 54 to 70 mg/dL, is presented here.

Time frame:
During the first 10 days of therapy
Reported as:
Count of participants · Participants
Number of Participants With an Episode of Hypoglycemia While Hospitalized
ParticipantsDegludecGlargine
Number of Participants With an Episode of Hypoglycemia While Hospitalized1415
SecondaryNumber of Participants With an Episode of Clinically Significant Hypoglycemia While Hospitalized

Blood glucose was measured before each meal and at bedtime. The number of participants with at least one episode of clinically significant hypoglycemia, defined as BG \< 54 mg/dL, is presented here.

Time frame:
During the first 10 days of therapy
Reported as:
Count of participants · Participants
Number of Participants With an Episode of Clinically Significant Hypoglycemia While Hospitalized
ParticipantsDegludecGlargine
Number of Participants With an Episode of Clinically Significant Hypoglycemia While Hospitalized31
SecondaryNumber of Participants With an Episode of Severe Hypoglycemia While Hospitalized

Blood glucose as measured before each meal and at bedtime. The number of participants with at least one episode of severe hypoglycemia, defined as BG \< 40 mg/dL, is presented here.

Time frame:
During the first 10 days of therapy
Reported as:
Count of participants · Participants
Number of Participants With an Episode of Severe Hypoglycemia While Hospitalized
ParticipantsDegludecGlargine
Number of Participants With an Episode of Severe Hypoglycemia While Hospitalized00
SecondaryNumber of Participants With an Episode of Severe Hyperglycemia While Hospitalized

Blood glucose was measured before each meal and at bedtime. The number of participants who experienced at least one episode of severe hyperglycemia, defined as BG \> 240 mg/dL, is presented here.

Time frame:
During the first 10 days of therapy
Reported as:
Count of participants · Participants
Number of Participants With an Episode of Severe Hyperglycemia While Hospitalized
ParticipantsDegludecGlargine
Number of Participants With an Episode of Severe Hyperglycemia While Hospitalized5247
SecondaryDaily Dose of Insulin in Hospitalized Patients

Electronic medical records and nursing records documented the day day and time of insulin administration, including the basal study drug given once daily (degludec or glargine), prandial insulin given before meals (aspart), and supplemental insulin given to correct hyperglycemia. The mean daily doses of basal insulin, prandial insulin, and total daily dose of insulin given to hospitalized patients are presented here.

Time frame:
During the first 10 days of therapy
Reported as:
Mean · International Units of insulin
Daily Dose of Insulin in Hospitalized Patients
International Units of insulinDegludecGlargine
Basal Insulin30 ± 1330 ± 18
Prandial Insulin11 ± 912 ± 11
Total Daily Dose of Insulin56 ± 2460 ± 36
SecondaryHemoglobin A1c (HbA1c) in Discharged Patients

The HbA1C test reflects the average of a person's blood glucose levels over the past 3 months by measuring the percentage of red blood cells (RBCs) with glycated hemoglobin (hemoglobin with glucose bonded to it). Participants with HbA1C ≥ 7.5% were followed for 12 weeks after hospital discharge. Samples for HbA1C were drawn at 4 and 12 weeks post-discharge. An HbA1c measurement below 5.7% is considered normal, while a measurement of 6.5% or greater indicates diabetes.

Time frame:
4 and 12 weeks after hospital discharge
Reported as:
Mean · percent of RBCs with glycated hemoglobin
Hemoglobin A1c (HbA1c) in Discharged Patients
percent of RBCs with glycated hemoglobinDegludecGlargine
4 weeks post-discharge8.3 ± 1.48.0 ± 1.4
12 weeks post-discharge8.2 ± 1.97.4 ± 1.6
SecondaryNumber of Hypoglycemia Episodes in Discharged Patients

Blood glucose was measured before each meal and at bedtime. The number of hypoglycemia episodes, defined as BG \< 70 mg/dL, was recorded via bi-weekly phone interviews and during 4 and 12 week outpatient study visits.

Time frame:
Up to 12 weeks after hospital discharge
Reported as:
Number · episodes of hypoglycemia
Number of Hypoglycemia Episodes in Discharged Patients
episodes of hypoglycemiaDegludecGlargine
Number of Hypoglycemia Episodes in Discharged Patients1619
SecondaryNumber of Clinically Significant Hypoglycemia Episodes in Discharged Patients

Blood glucose will be measured before each meal and at bedtime. The number of episodes of clinically significant hypoglycemia, defined as BG \< 54 mg/dL, are presented here.

Time frame:
Up to 12 weeks after hospital discharge
Reported as:
Number · episodes of significant hypoglycemia
Number of Clinically Significant Hypoglycemia Episodes in Discharged Patients
episodes of significant hypoglycemiaDegludecGlargine
Number of Clinically Significant Hypoglycemia Episodes in Discharged Patients11
SecondaryNumber of Episodes of Severe Hyperglycemia in Discharged Patients

Blood glucose was measured before each meal and at bedtime. The number of episodes of severe hyperglycemia, defined as BG \> 240 mg/dL, are presented here.

Time frame:
Up to 12 weeks after hospital discharge
Reported as:
Number · episodes of severe hyperglycemia
Number of Episodes of Severe Hyperglycemia in Discharged Patients
episodes of severe hyperglycemiaDegludecGlargine
Number of Episodes of Severe Hyperglycemia in Discharged Patients21155
Other pre-specifiedNumber of Participants Experiencing Cardiac Complications During Hospitalization

Cardiac complications during hospitalization were examined as a composite of complications, defined as myocardial infarction, cardiac arrhythmia requiring medical treatment, or cardiac arrest. The number of participants experiencing cardiac complications while hospitalized patients is presented here.

Time frame:
During the first 10 days of therapy
Reported as:
Count of participants · Participants
Number of Participants Experiencing Cardiac Complications During Hospitalization
ParticipantsDegludecGlargine
Number of Participants Experiencing Cardiac Complications During Hospitalization00
Other pre-specifiedNumber of Participants With Acute Kidney Injury During Hospitalization

Acute kidney injury defined as an increase in serum creatinine ≥ 0.3 mg/dL from baseline or ≥1.5 times baseline creatinine, per Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. The number of participants experiencing acute kidney injury during hospitalization is presented here.

Time frame:
During the first 10 days of therapy
Reported as:
Count of participants · Participants
Number of Participants With Acute Kidney Injury During Hospitalization
ParticipantsDegludecGlargine
Number of Participants With Acute Kidney Injury During Hospitalization510
Other pre-specifiedLength of Hospital Stay

The length of hospital in days is presented here.

Time frame:
Duration of hospital stay (an average of 10 days)
Reported as:
Median · days
Length of Hospital Stay
daysDegludecGlargine
Length of Hospital Stay6.7 (4.7 to 10.5)7.5 (4.7 to 11.6)
Other pre-specifiedNumber of Participants Who Died During Hospitalization

Hospital mortality is evaluated as the number of deaths among participants during hospitalization.

Time frame:
Duration of hospital stay (an average of 10 days)
Reported as:
Count of participants · Participants
Number of Participants Who Died During Hospitalization
ParticipantsDegludecGlargine
Number of Participants Who Died During Hospitalization01
Other pre-specifiedNumber of Participants Experiencing Acute Kidney Injury in Discharged Patients

Acute kidney injury defined as an increase in serum creatinine ≥ 0.3 mg/dL from baseline or ≥1.5 times baseline creatinine, per Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. The number of participants experiencing acute kidney injury after hospital discharge is presented here.

Time frame:
Up to 12 weeks after hospital discharge
Reported as:
Count of participants · Participants
Number of Participants Experiencing Acute Kidney Injury in Discharged Patients
ParticipantsDegludecGlargine
Number of Participants Experiencing Acute Kidney Injury in Discharged Patients10

Adverse events

Collected over Information on adverse events was collected from the time of consent during hospitalization for up to 3 months after hospital discharge.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Degludec1/82 (1.2%)3/82 (3.7%)3/82 (3.7%)
Glargine1/79 (1.3%)3/79 (3.8%)3/79 (3.8%)
Most frequent serious events
Most frequent serious events
EventDegludecGlargine
Hospital readmission for chest painCardiac disorders0/821/79
Hospital readmission for urinary tract infectionRenal and urinary disorders0/821/79
Hospital readmission for head injuryNervous system disorders0/821/79
Hospital readmisson for non-healing amputation stumpInfections and infestations1/820/79
Hospital readmission for heart failureCardiac disorders1/820/79
Severe hypoglycemiaEndocrine disorders1/820/79
Most frequent other events
Most frequent other events
EventDegludecGlargine
Emergency room visit for blunt chest traumaMusculoskeletal and connective tissue disorders0/821/79
Emergency room visit for right eye medial styeEye disorders0/821/79
Emergency room visit for orthostatic hypotensionCardiac disorders0/821/79
Emergency room visit for bilateral knee painMusculoskeletal and connective tissue disorders1/820/79
Emergency room visit for wound infectionInfections and infestations1/820/79
Emergency room visit for congestive heart failureCardiac disorders1/820/79

Baseline characteristics

The baseline analysis population includes participants who completed the inpatient portion of the study and had at least two doses of the study medication.

Age, Continuous
Age, Continuous(Years)DegludecGlargineTotal
Mean55.6 ± 1256.7 ± 1056.2 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)DegludecGlargineTotal
Female352560
Male4754101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DegludecGlargineTotal
Hispanic or Latino81018
Not Hispanic or Latino7469143
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DegludecGlargineTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander101
Black or African American5856114
White161834
More than one race7512
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)DegludecGlargineTotal
United States8279161
Body Mass Index
Body Mass Index(kg/m^2)DegludecGlargineTotal
Mean36 ± 936 ± 1236 ± 11
Home diabetes treatment
Home diabetes treatment(Participants)DegludecGlargineTotal
No treatment71017
Oral diabetic agents181533
Insulin only303262
Insulin plus oral diabetic agent272148
Glucagon-like peptide-1 receptor agonists (GLP-1RA)011
08

Study locations

4 sites
  • Grady Hospital
    Atlanta, Georgia 30308, United States
  • Emory University Hospital Clinical Research Network
    Atlanta, Georgia 30322, United States
  • Mount Sinai
    New York, New York 10029, United States
  • Providence Medical Research Centre
    Spokane, Washington 99204, United States
09

References and documents

Publications

  • Galindo RJ, Pasquel FJ, Vellanki P, Alicic R, Lam DW, Fayfman M, Migdal AL, Davis GM, Cardona S, Urrutia MA, Perez-Guzman C, Zamudio-Coronado KW, Peng L, Tuttle KR, Umpierrez GE. Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes. Diabetes Obes Metab. 2022 Jan;24(1):42-49. doi: 10.1111/dom.14544. Epub 2021 Sep 24. PubMed 34490700 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The research team will share individual participant data that underlie the results reported in this study, after deidentification.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available for sharing starting 6 months after publication and up to 5 years after publication.

Access criteria: Access will be given to researchers who provide a methodologically sound proposal to achieve the aims in their approved proposal. Proposals should be directed to geumpie@emory.edu. To gain access, data requestors will need to sign a data access agreement.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Mar 2021, 37 months.

Results were first posted in Mar 2022, 1 year after primary completion.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's 37 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2017
First posted
Nov 8, 2017
StartActual
Jan 2, 2018
Primary completionActual
Mar 1, 2021
CompletionActual
Mar 1, 2021
Results first posted
Mar 31, 2022
Last update
Mar 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03336528
Lead sponsor
Emory University
Collaborators
Novo Nordisk A/S
Responsible party
Guillermo Umpierrez (Professor, Emory University) — Principal investigator
First posted
Nov 8, 2017
Start date
Jan 2, 2018
Primary completion
Mar 1, 2021
Completion
Mar 1, 2021
Results posted
Mar 31, 2022
Last update
Mar 31, 2022

Study contacts

Guillermo Umpierrez, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin degludec

Start the discussion